About - Annexon Biosciences
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	



		
		
	





 



  

	
leadership
advancing transformative therapies

OUR MISSION

We’re passionate about bringing game-changing therapies to patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders

OUR History

2007

Annexon co-founder Ben Barres discovered that C1q drives synapse loss and disease progression in neurodegenerative disorders

C1q also known to drive tissue damage in antibody-mediated autoimmune disease

2014

Completed Series A financing

Developed ANX005 and other classical pathway inhibitors (C1q, C1s, C2, C4)

2016

Demonstrated importance of inhibiting C1q at the top of the pathway, blocking activity before it starts

2017

ANX005: clinical POC in GBS as lead antibody-mediated autoimmune indication

2019

ANX007: Full target engagement in the eye with intravitreal administration in glaucoma patients

2020

Annexon’s IPO spurs pipeline and organizational growth

2021

ANX009: Full target engagement in the blood space with subcutaneous administration in healthy volunteers

today

Foundation established for next generation classical complement platform

Our Leadership

Our proven and passionate leadership team has a successful track record of discovering, developing and commercializing breakthrough therapeutics for the disease indications we are pursuing. We are deeply committed to leveraging our science to develop novel C1q inhibitors for the treatment of patients with antibody-mediated autoimmune diseases and complement-mediated neurodegenerative diseases.

Douglas Love, Esq.

PRESIDENT &
CHIEF EXECUTIVE OFFICER

Ted Yednock, PhD

EVP & CHIEF INNOVATION OFFICER

Larry C. Mattheakis, PhD

EVP & CHIEF SCIENTIFIC OFFICER

Sanjay Keswani, MBBS, FRCP

EVP & CHIEF MEDICAL OFFICER

Jennifer Lew

EVP & CHIEF FINANCIAL OFFICER

Michael Overdorf, MBA

EVP & CHIEF BUSINESS OFFICER

Our Board of Directors

Annexon’s Board of Directors is comprised of accomplished leaders in biotechnology and investments, with expertise in corporate governance, research and development, commercialization and finance.

Thomas G. Wiggans

BOARD CHAIR BOARD CHAIR, FORMER FOUNDER, CHAIRMAN & CEO DERMIRA

William H. Carson, MD

BOARD MEMBER

Jung E. Choi

BOARD MEMBER CHIEF BUSINESS AND STRATEGY OFFICER GLOBAL BLOOD THERAPEUTICS

Douglas Love, Esq.

PRESIDENT & CEO ANNEXON

Muneer Satter

BOARD MEMBERMANAGING PARTNERSATTER INVESTMENT MANAGEMENT

Ricky Sun, PhD

BOARD MEMBER PARTNER BAIN CAPITAL LIFE SCIENCES

Will Waddill

BOARD MEMBER

Scientific Advisory Board

Jeff Goldberg, MD, PhD

PROFESSOR AND CHAIR OF OPHTHALMOLOGY, BYERS EYE INSTITUTE, STANFORD UNIVERSITY

Stephen Hauser, MD

ROBERT A. FISHMAN DISTINGUISHED PROFESSOR CHAIR, DEPARTMENT OF NEUROLOGY, UCSF

David Holtzman, MD

PROFESSOR AND CHAIRMAN, DEPARTMENT OF NEUROLOGY, WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

Tom Maniatis, PhD

CHAIR, DEPARTMENT OF BIOCHEMISTRY, COLUMBIA UNIVERSITY

Beth Stevens, PhD

ASSISTANT PROFESSOR NEUROLOGY, CHILDREN’S HOSPITAL BOSTON, HARVARD MEDICAL SCHOOL

Hugh Willison, MD

PROFESSOR OF NEUROLOGY, UNIVERSITY OF GLASGOW

Contact

ANNEXON BIOSCIENCES, INC.
1400 Sierra Point Parkway
Building C, 2nd Floor
Brisbane, CA 94005

info@annexonbio.com
Phone: 650.822.5500
Fax: 650.636.9773